ElevateBio, LLC, is a Cambridge-based biotechnology holding company, established to create and operate a broad portfolio of cell and gene therapy companies through partnerships with leading academic researchers, medical centers and entrepreneurs. ElevateBio builds single- and multi-product companies by providing scientific founders with fully-integrated bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug developers and commercial expertise. ElevateBio is building a team of industry leaders who work at the holding company and are assigned exclusively or in-part to ElevateBio portfolio companies over time. ElevateBio BaseCamp, a company-owned center of cell and gene therapy innovation, will serve as the R&D, process development and manufacturing hub across the entire ElevateBio portfolio while also supporting selected strategic partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/13/19 | $150,000,000 | Series A |
EcoR1 Capital F2 Ventures Redmile Group Samsara BioCapital UBS Oncology Impact Fund | undisclosed |
| 03/30/20 | $170,000,000 | Series B |
EcoR1 Capital EDBI F2 Ventures MPM Capital Redmile Group Samsara BioCapital Surveyor Capital The Invus Group Vertex Ventures | undisclosed |
| 03/16/21 | $525,000,000 | Series C |
EcoR1 Capital EDBI Emerson Collective F2 Capital Fidelity Management & Research Company Invus Matrix Capital Management MPM Capital Redmile Group Samsara BioCapital SoftBank Vision Fund 2 Surveyor Capital | undisclosed |
| 05/24/23 | $401,000,000 | Series D |
AyurMaya EcoR1 Capital EDBI Emerson Collective F2 Capital Fidelity Management & Research Company Invus ITOCHU Corporation Lee Family MPM Capital Novo Nordisk Redmile Group Samsara BioCapital SoftBank Vision Fund 2 Surveyor Capital Vertex Ventures Woodline Partners | undisclosed |
